The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor
Open accessAbstract
The bromodomain‐containing proteins BRD9 and BRD7 are part of the human SWI/SNF chromatin‐remodeling complexes BAF and PBAF. To date, no selective inhibitor for BRD7/9 has been reported despite its potential value as a biological tool or as a lead for future therapeutics. The quinolone‐fused lactam LP99 is now reported as the first potent and selective inhibitor of the BRD7 and BRD9 bromodomains. Development of LP99 from a fragment hit was expedited through balancing structure‐based inhibitor design and biophysical characterization against tractable chemical synthesis: Complexity‐building nitro‐Mannich/lactamization cascade processes allowed for early structure–activity relationship studies whereas an enantioselective organocatalytic nitro‐Mannich reaction enabled the synthesis of the lead scaffold in enantioenriched form and on scale. This epigenetic probe was shown to inhibit the association of BRD7 and BRD9 to acetylated histones in vitro and in cells. Moreover, LP99 was used to demonstrate that BRD7/9 plays a role in regulating pro‐inflammatory cytokine secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheinecker, C., Smolen, J., Yasothan, U., Stoll, J., & Kirkpatrick, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2863 · Cited by 49
Cited by
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 413
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Klucznik, T., Mikulak-Klucznik, B., McCormack, M. P., Lima, H., Szymkuć, S., Bhowmick, M., Molga, K., Zhou, Y., Rickershauser, L., Gajewska, E. P., et al. (2018) · Chem · doi:10.1016/j.chempr.2018.02.002 · Cited by 352
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Zoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336
Self-citation
Metadata
- Authors
- Clark, P. G. K., Vieira, L. C. C., Tallant, C., Fedorov, O., Singleton, D. C., Rogers, C. M., Monteiro, O. P., Bennett, J. M., Baronio, R., Müller, S., Daniels, D. L., Méndez, J., Knapp, S., Brennan, P. E., & Dixon, D. J.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2015-04-13
- Volume
- 54
- Issue
- 21
- Pages
- 6217-6221
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W4237388197
- Cited by
- 164
- References
- 1
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. https://app.cochat.ai/papers/10.1002/anie.201501394
- The paper
- Clark, P. G. K., Vieira, L. C. C., Tallant, C., Fedorov, O., Singleton, D. C., Rogers, C. M., Monteiro, O. P., Bennett, J. M., Baronio, R., Müller, S., Daniels, D. L., Méndez, J., Knapp, S., Brennan, P. E., & Dixon, D. J. (2015). LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.201501394
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.